LBLuca Bragina

Luca Bragina

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Luca Bragina has a total of 25 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Expression of Neurofilament Subunits at Neocortical Glutamatergic and GABAergic Synapses

    by Luca Bragina, Fiorenzo Conti

    Neurofilaments (NFs) are neuron-specific heteropolymers that have long been considered as structural proteins. However, it has recently been documented that they may play a functional role at synapses. Indeed, the four NF subunits—NFL, NFM, NFH and α-internexin—are integral components of synapses in the striatum and hippocampus, since their elimination disrupts synaptic plasticity and impairs social memory, an observation that might have important implications for some neuropsychiatric diseases. Here, we studied NFs localization in VGLUT1-, VGLUT2-, VGAT-, PSD-95- and gephyrin-positive (+) puncta, and in glutamatergic and GABAergic synapses in the cerebral cortex of adult rats. Synapses were identified by pre- and postsynaptic markers: glutamatergic synapses by VGLUT1+ or VGLUT2+ puncta contacting PSD-95+ puncta; and GABAergic synapses by VGAT+ puncta contacting gephyrin+ puncta. In VGLUT1 glutamatergic synapses NF showed a greater expression in the compartment labeled by postsynaptic markers (20%–30%) than in those labeled by presynaptic markers (10%–20%), whereas in GABAergic synapses a similar expression was detected in both compartments (20%–30%). Moreover, NF expression was higher in the GABAergic (20%–30%) than in the glutamatergic (10%–15%) compartments labeled by presynaptic markers. Finally, a higher colocalization of VGLUT1+, VGLUT2+ and VGAT+ puncta with NFs was seen when presynaptic puncta contacted elements labeled by postsynaptic markers. These findings show that the four NF subunits are expressed at some neocortical synapses, and contribute to glutamatergic and GABAergic synapse heterogeneity.


  • Open Access

    Differential expression of metabotropic glutamate and GABA receptors at neocortical glutamatergic and GABAergic axon terminals

    by Luca Bragina, Tiziana Bonifacino, Silvia Bassi, Marco Milanese, Giambattista Bonanno, Fiorenzo Conti

    Metabotropic glutamate receptors (mGluRs) and GABAB receptors are highly expressed at presynaptic sites. To verify the possibility that the two classes of metabotropic receptors contribute to axon terminals heterogeneity, we studied the localization of mGluR1α, mGluR5, mGluR2/3, mGluR7 and GABAB1 in VGLUT1-, VGLUT2- and VGAT-positive terminals in the cerebral cortex of adult rats. VGLUT1-positive puncta expressed mGluR1α (~5%), mGluR5 (~6%), mGluR2/3 (~22%), mGluR7 (~17%), and GABAB1 (~40%); VGLUT2-positive terminals expressed mGluR1α (~10%), mGluR5 (~11%), mGluR2/3 (~20%), mGluR7 (~28%), and GABAB1 (~25%); whereas VGAT-positive puncta expressed mGluR1α (~27%), mGluR5 (~24%), mGluR2/3 (~38%), mGluR7 (~31%), and GABAB1 (~19%). Control experiments ruled out the possibility that post-synaptic mGluRs and GABAB1 might have significantly biased our results. We also performed functional assays in synaptosomal preparations, and showed that all agonists modify Glu and GABA levels, which return to baseline upon exposure to antagonists. Overall, these findings indicate that mGluR1α, mGluR5, mGluR2/3, mGluR7 and GABAB1 expression differ significantly between glutamatergic and GABAergic axon terminals, and that the robust expression of heteroreceptors may contribute to the homeostatic regulation of the balance between excitation and inhibition.


  • Open Access

    Heterogeneity of presynaptic proteins: do not forget isoforms

    by Luca Bragina, Giorgia Fattorini, Silvia Giovedì, Federica Bosco, Fabio Benfenati, Fiorenzo Conti

    Analysis of presynaptic protein expression in glutamatergic and GABAergic central synapses performed in several laboratories and with different techniques is unveiling a complex scenario, largely because each presynaptic protein exists in several isoforms. The interpretation of these findings is generally based on the notion that each synapse and each synaptic vesicle contains one of the isoforms of each family of presynaptic proteins. We verified whether this interpretation is tenable by performing triple labeling and immunoisolation studies with the aim of detecting two isoforms of a given presynaptic protein in glutamatergic or GABAergic axon terminals and/or synaptic vesicles. Here, we show that: 1) the possibility that not all families of presynaptic proteins are expressed in all terminals must be taken into serious account; 2) the expression of a given protein isoform in a terminal does not exclude the expression of other isoforms of the same protein in the same terminal and in the same vesicle. These conclusions open new and interesting problems; their experimental analysis might improve our understanding of the physiology and patophysiology of central synapses.


  • Open Access

    Analysis of Synaptotagmin, SV2, and Rab3 Expression in Cortical Glutamatergic and GABAergic Axon Terminals

    by Luca Bragina, Giorgia Fattorini, Silvia Giovedí, Marcello Melone, Federica Bosco, Fabio Benfenati, Fiorenzo Conti

    We investigated whether cortical glutamatergic and GABAergic release machineries can be differentiated on the basis of the nature and amount of proteins they express, by performing a quantitative analysis of the degree of co-localization of synaptotagmin (SYT) 1 and 2, synaptic vesicle protein 2 (SV2) A and B, and Rab3a and c in VGLUT1+, VGLUT2+, and VGAT+ terminals and synaptic vesicles in rat cerebral cortex. Co-localization studies showed that SYT1 was expressed in 60% of VGLUT1 and VGLUT2 puncta and 50% of VGAT puncta; SYT2 in 30% of VGLUT1 and VGLUT2 puncta, and in 80% of VGAT puncta; SV2A in 80% of VGLUT1, 40% of VGLUT2, and >90% of VGAT puncta; SV2B in 90% of VGLUT1, 45% of VGLUT2, and 15% VGAT puncta; Rab3a in 80% of VGLUT1, 40% in VGLUT2, and 60% in VGAT puncta; and Rab3c in 20% VGLUT1, 40% VGLUT2, and 60% in VGAT puncta. None of the proteins studied exhibited a differential laminar distribution. Since SV2B is reportedly expressed by glutamatergic neurons and we observed SV2B expression in VGAT puncta, we performed electron microscopic studies and found SV2B positive axon terminals forming symmetric synapses. Immunoisolation studies showed that the expression levels of the protein isoforms varied in the three populations of SVs. Expression of SYT1 was highest in VGLUT1-SVs, while SYT2 expression was similar in the three SV groups. Expression of SV2A was similarly high in all three SV populations, except for SV2B levels that were very low in VGAT-SVs. Finally, Rab3a levels were similar in the three SV groups, while Rab3c levels were highest in VGLUT1-SVs. These quantitative results extend our previous studies on the differential expression of presynaptic proteins involved in neurotransmitter release in GABAergic and glutamatergic terminals and indicate that heterogeneity of the respective release machineries can be generated by the differential complement of synaptic vesicle proteins involved in distinct stages of the release process.


  • Open Access

    A Role for GAT-1 in Presynaptic GABA Homeostasis?

    by Fiorenzo Conti, Marcello Melone, Giorgia Fattorini, Luca Bragina, Silvia Ciappelloni

    In monoamine-releasing terminals, neurotransmitter transporters – in addition to terminating synaptic transmission by clearing released transmitters from the extracellular space - are the primary mechanism for replenishing transmitter stores and thus regulate presynaptic homeostasis. Here, we analyze whether GAT-1, the main plasma membrane GABA transporter, plays a similar role in GABAergic terminals. Re-examination of existing literature and recent data gathered in our laboratory show that GABA homeostasis in GABAergic terminals is dominated by the activity of the GABA synthesizing enzyme and that GAT-1-mediated GABA transport contributes to cytosolic GABA levels. However, analysis of GAT-1 KO, besides demonstrating the effects of reduced clearance, reveals the existence of changes compatible with an impaired presynaptic function, as mIPSCs frequency is reduced by one third and GADs and PAG levels are significantly up-regulated. Although the changes observed are less robust than those reported in mice with impaired dopamine, noradrenaline and serotonin plasma membrane transporters, they suggest that in GABAergic terminals GAT-1 impacts on presynaptic GABA homeostasis, and may contribute to the activity-dependent regulation of inh


  • Acute phencyclidine administration reduces extracellular glutamate levels and the expression of synaptophysin and SNAP-25 in rat frontal cortex

    by Giorgia Fattorini, Luca Bragina, Chiara Candiracci, Marcello Melone, Andrea Cozzi, Domenico E. Pellegrini-Giampietro, Fiorenzo Conti


  • GLT‐1 expression and Glu uptake in rat cerebral cortex are increased by phencyclidine

    by Giorgia Fattorini, Marcello Melone, Luca Bragina, Chiara Candiracci, Andrea Cozzi, Domenico E. Pellegrini Giampietro, Monica Torres‐Ramos, Alberto Pérez‐Samartín, Carlos Matute, Fiorenzo Conti

    Using western blottings, microdialysis, and functional assays we tested the hypothesis that phencyclidine (PCP) modifies the expression and function of glutamate (Glu) transporters in the rat frontal cortex. Western blotting studies revealed that administration of PCP (10 mg/kg/day; 7 days) increased significantly the expression of the astrocytic Glu transporter GLT‐1/EAAT2. Functional studies showed that PCP increased significantly Na+‐dependent Glu uptake in slices and in neuron/astrocyte co‐cultures, and microdialysis studies evidenced that PCP treatment reduced basal Glu output. In our experimental conditions, PCP did not induce toxicity. These studies show that PCP increases the expression of GLT‐1 in the cerebral cortex, thereby increasing Glu uptake and reducing extracellular [Glu].


  • GAT‐1 regulates both tonic and phasic GABAA receptor‐mediated inhibition in the cerebral cortex

    by Luca Bragina, Ivan Marchionni, Azar Omrani, Andrea Cozzi, Domenico E. Pellegrini‐Giampietro, Enrico Cherubini, Fiorenzo Conti

    γ‐Aminobutyric acid 1 (GAT‐1) is the most copiously expressed GABA transporter; we studied its role in phasic and tonic inhibition in the neocortex using GAT‐1 knockout (KO) mice. Immunoblotting and immunocytochemical studies showed that GAT‐2 and GAT‐3 levels in KOs were unchanged and that GAT‐3 was not redistributed in KOs. Moreover, the expression of GAD65/67 was increased, whereas that of GABA or VGAT was unchanged. Microdialysis studies showed that in KOs spontaneous extracellular release of GABA and glutamate was comparable in WT and KO mice, whereas KCl‐evoked output of GABA, but not of glutamate, was significantly increased in KOs. Recordings from layer II/III pyramids revealed a significant increase in GABAAR‐mediated tonic conductance in KO mice. The frequency, amplitude and kinetics of spontaneous inhibitory post‐synaptic currents (IPSCs) were unchanged, whereas the decay time of evoked IPSCs was significantly prolonged in KO mice. In KO mice, high frequency stimulation of GABAergic terminals induced large GABAAR‐mediated inward currents associated with a reduction in amplitude and decay time of IPSCs evoked immediately after the train. The recovery process was slower in KO than in WT mice. These studies show that in the cerebral cortex of GAT‐1 KO mice GAT‐3 is not redistributed and GADs are adaptively changed and indicate that GAT‐1 has a prominent role in both tonic and phasic GABAAR‐mediated inhibition, in particular during sustained neuronal activity.


  • Open Access

    GLT‐1 down‐regulation induced by clozapine in rat frontal cortex is associated with synaptophysin up‐regulation

    by Luca Bragina, Marcello Melone, Giorgia Fattorini, Monica Torres‐Ramos, Ainara Vallejo‐Illarramendi, Carlos Matute, Fiorenzo Conti

    In rat frontal cortex, extracellular levels of glutamate are raised by the anti‐psychotic drug clozapine. We have recently shown that a significant reduction in the levels of the glutamate transporter GLT‐1 may be one of the mechanisms responsible for this elevation. Here we studied whether GLT‐1 down‐regulation induced by chronic clozapine treatment is associated with changes in the expression of synaptophysin, synaptosome‐associated protein of 25 kDa (SNAP‐25) and vesicular glutamate transporter 1 (VGLUT1), three major presynaptic proteins involved in neurotransmitter release. Quantitative high‐resolution confocal microscopy studies in vivo showed that GLT‐1 down‐regulation is closely associated with a significant increase in synaptophysin, but not SNAP‐25 and VGLUT1, expression. This was confirmed in vitro studies, and in western blotting studies of synaptophysin, SNAP‐25 and VGLUT1. In addition, our results show that, following clozapine treatment, synaptophysin expression increases in the very cortical regions in which GLT‐1 expression is down‐regulated. These findings suggest that part of the effects of clozapine may be exerted via an action on the presynaptic machinery involved in neurotransmitter release.